BG Medicine is expected to pursue development and validation of an immunoassay and investigate its clinical utility as a biomarker. If successful, BG Medicine plans to complete the development and validation studies and seek regulatory clearance for the test.

As per the agreement, Merck has granted BG Medicine a semi-exclusive license to certain Merck intellectual property and technologies for use and development of a candidate in-vitro diagnostic test in exchange for certain testing services, data sharing and other considerations. BG Medicine is eligible for certain payments upon achievement of established milestones.

Pieter Muntendam, president and CEO of BG Medicine, said: “This project holds the potential to improve the management of a common disorder that plays an important role in the risk for heart attack and stroke, two of the most deadly medical conditions of our time.”